Surgical treatment of obesity.
More than half of the European population are overweight (body mass index (BMI) > 25 and < 30 kg/m2) and up to 30% are obese (BMI > or = 30 kg/m2). Being overweight and obesity are becoming endemic, particularly because of increasing nourishment and a decrease in physical exercise. Insulin resistance, type 2 diabetes, dyslipidemia, hypertension, cholelithiasis, certain forms of cancer, steatosis hepatis, gastroesophageal reflux, obstructive sleep apnea, degenerative joint disease, gout, lower back pain, and polycystic ovary syndrome are all associated with overweight and obesity. The endemic extent of overweight and obesity with its associated comorbidities has led to the development of therapies aimed at weight loss. The long-term effects of diet, exercise, and medical therapy on weight are relatively poor. With respect to durable weight reduction, bariatric surgery is the most effective long-term treatment for obesity with the greatest chances for amelioration and even resolution of obesity-associated complications. Recent evidence shows that bariatric surgery for severe obesity is associated with decreased overall mortality. However, serious complications can occur and therefore a careful selection of patients is of utmost importance. Bariatric surgery should at least be considered for all patients with a BMI of more than 40 kg/m2 and for those with a BMI of more than 35 kg/m2 with concomitant obesity-related conditions after failure of conventional treatment. The importance of weight loss and results of conventional treatment will be discussed first. Currently used operative treatments for obesity and their effectiveness and complications are described. Proposed criteria for bariatric surgery are given. Also, some attention is devoted to more basic insights that bariatric surgery has provided. Finally we deal with unsolved questions and future directions for research.
Bult
Mariëlle J F
MJ
Department of Internal Medicine, Diakonessenhuis Utrecht, Bosboomstraat 1, 3582 KE Utrecht, The Netherlands.
van Dalen
Thijs
T
Muller
Alex F
AF
D019440:Anti-Obesity Agents / Q000627:therapeutic use; D001067:Appetite Depressants / Q000627:therapeutic use; D050110:Bariatric Surgery / Q000009:adverse effects / Q000379:methods / Q000401:mortality; D001662:Biliary Tract Surgical Procedures; D015992:Body Mass Index; D015897:Comorbidity; D003920:Diabetes Mellitus / Q000517:prevention & control; D002149:Energy Intake; D005060:Europe / Q000453:epidemiology; D015444:Exercise; D015390:Gastric Bypass; D015391:Gastroplasty; D006801:Humans; D008055:Lipids / Q000097:blood; D009767:Obesity, Morbid / Q000150:complications / Q000453:epidemiology / Q000209:etiology / Q000401:mortality / Q000601:surgery* / Q000628:therapy; D050177:Overweight; D018579:Patient Selection; D011788:Quality of Life; D012307:Risk Factors; D012720:Severity of Illness Index; D016896:Treatment Outcome; D015431:Weight Loss
D019440:Anti-Obesity Agents; D001067:Appetite Depressants; D008055:Lipids